Toward a poliovirus-based simian immunodeficiency virus vaccine: Correlation between genetic stability and immunogenicity

Journal of Virology

Volumn 71, Issue 10, 1997, Pages 7841-7850

  Tang, Shenbei ^a   Van Rij, Ronald ^a   Silvera, Deborah ^a   Andino, Raul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE; VIRUS VECTOR;

ACTIVE IMMUNIZATION; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; GENE INSERTION; HEAT SENSITIVITY; HELA CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOLECULAR STABILITY; MOUSE; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSGENIC MOUSE; VACCINE PRODUCTION; VIRUS REPLICATION;

EID: 0030760964     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.10.7841-7850.1997     Document Type: Article

References (37)

1. Alexander, L., H. H. Lu, M. Gromeier, and E. Wimmer. 1994. Dicistronic polioviruses as expression vectors for foreign genes. AIDS Res. Hum. Retroviruses 10(Suppl 2):S57-S60.
2. Anderson, M. J., D. C. Porter, P. N. Fultz, and C. D. Morrow. 1996. Poliovirus replicons that express the gag or the envelope surface protein of simian immunodeficiency virus SIV(smm) PBJ14. Virology 219:140-149.
3. Andino, R. 1994. Unpublished results.
4. Andino, R., G. E. Rieckhof, P. L. Achacoso, and D. Baltimore. 1993. Poliovirus RNA synthesis utilizes an RNP complex formed around the 57prime;-end of viral RNA. EMBO J. 12:3587-3598.
5. Andino, R., D. Silvera, S. D. Suggett, P. L. Achacoso, C. J. Miller, D. Baltimore, and M. B. Feinberg. 1994. Engineering pofiovirus as a vaccine vector for the expression of diverse antigens. Science 265:1448-1451.
6. Ansardi, D. C., R. Pal Ghosh, D. Porter, and C. D. Morrow. 1995. Encapsidation and serial passage of a poliovirus replicon which expresses an inactive 2A proteinase. J. Virol. 69:1359-1366.
7. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). 1994. Current protocols in molecular biology, vol. 2. Green Publishing Associates and Wiley-Interscience, New York, N.Y.
8. Burke, K. L., G. Dunn, M. Ferguson, P. D. Minor, and J. W. Almond. 1988. Antigen chimaeras of poliovirus as potential new vaccines. Nature 332:81-82.
9. Choi, W. S., R. Pal-Ghosh, and C. D. Morrow. 1991. Expression of human immunodeficiency virus type 1 (HIV-1) Gag, Pol, and Env proteins from chimeric HIV-1-poliovirus minireplicons. J. Virol. 65:2875-2883.
10. Cooney, E. L., M. J. McElrath, L. Corey, S. L. Hu, A. C. Collier, D. Arditti, M. Hoffman, R. W. Coombs, G. E. Smith, and P. D. Greenberg. 1993. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl. Acad. Sci. USA 90:1882-1886.
11. Evans, D. J., J. McKeating, J. M. Meredith, K. L. Burke, K. Katrak, A. John, M. Ferguson, P. D. Minor, R. A. Weiss, and J. W. Almond. 1989. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 339:385-388.
12. Forrest, B. D. 1993. Mucosal immunity: challenges for HIV vaccines, p. 327-343. In W. C. Koff, F. Wong-Staal, and R. C. Kennedy (ed.), AIDS research reviews, vol. 3. Marcel Dekker, Inc., New York, N.Y.
13. Forrest, B. D. 1991. Women, HIV, and mucosal immunity. Lancet 337:835-836.
14. Helen, C., and E. Wimmer. 1995. Enterovirus genetics, p. 25-72. In H. Rotbart (ed.), Human enterovirus infections. ASM Press, Washington, D.C.
15. Henry, J. L., E. S. Jaikaran, J. R. Davies, A. J. Tomlinson, P. J. Mason, J. M. Barnes, and A. J. Beale. 1966. A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J. Hyg. (London) 64:105-120.
16. Hu, S. L., K. Abrams, G. N. Barber, P. Moran, J. M. Zarling, A. J. Langlois, L. Kuller, W. R. Morion, and R. E. Benveniste. 1992. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456-459.
17. Karzon, D. T., D. P. Bolognesi, and W. C. Koff. 1992. Development of a vaccine for the prevention of AIDS, a critical appraisal. Vaccine 10:1039-1052.
18. Kirkegaard, K. 1992. Genetic analysis of picornaviruses. Curr. Opin. Genet. Dev. 2:64-70.
19. Kirkegaard, K., and D. Baltimore. 1986. The mechanism of RNA recombination in poliovirus. Cell 47:433-443.
20. Lu, H., L. Alexander, and E. Wimmer. 1995. Construction and genetic analysis of dicistronic polioviruses containing open reading frame for epitopes of human immunodeficiency virus type 1 gp120. J. Virol. 69:4797-4806.
21. Luthman, H., and G. Magnusson. 1983. High efficiency polyoma DNA transfection of chloroquine treated cells. Nucleic Acids Res. 11:1295-1308.
22. Magrath, D., D. Bainton, and M. Freeman. 1981. Response of children to a single dose of oral or inactivated polio vaccine. Dev. Biol. Stand. 47:223-226.
23. Marthas, M., S. Sutjipto, C. Miller, J. Higgins, J. Torten, R. Unger, H. Kiyono, J. McGhee, P. Marx, and N. Pedersen. 1992. Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against intravenous and intravaginal challenge, p. 117-122. In F. Brown, R. M. Chanock, H. S. Ginsberg, et al. (ed.), Vaccines 1992. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
24. Mattion, N. M., P. A. Reilly, S. J. DiMichele, J. C. Crowley, and C. WeeksLevy. 1994. Attenuated poliovirus strain as a live vector: expression of regions of rotavirus outer capsid protein VP7 by using recombinant Sabin 3 viruses. J. Virol. 68:3925-3933.
25. Melnick, J. L. 1988. Live attenuated poliovaccines, p. 115-157. In S. A. Plotkin and E. A. Mortimer, Jr. (ed.), Vaccines. W. B. Saunders Co., Philadelphia, Pa.
26. Merson, M. H. 1993. Slowing the spread of HIV: agenda for the 1990s. Science 260:1266-1268.
27. Moscufo, N., and M. Chow. 1992. Myristate-protein interactions in poliovirus: interactions of VP4 threonine 28 contribute to the structural conformation of assembly intermediates and the stability of assembled virions. J. Virol. 66:6849-6857.
28. Nishio, O., Y. Ishihara, K. Sakae, Y. Nonomura, A. Kuno, S. Yasukawa, H. Inoue, K. Miyamura, and R. Kono. 1984. The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. J. Biol. Stand. 12:1-10.
29. Pantaleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358.
30. Porter, D. C., D. C. Ansardi, and C. D. Morrow. 1995. Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 gag gene by using a complementation system which provides the P1 capsid protein in trans. J. Virol. 69:1548-1555.
31. Public Health Laboratory Service. 1965. The excretion of type 1 poliovirus after challenge following primary immunization with quadruple, Salk and Sabin vaccines. Mon. Bull. Minist. Health 24:365-369.
32. Rosenberg, A. H., B. N. Lade, D. S. Chui, S. W. Lin, J. J. Dunn, and F. W. Studier. 1987. Vectors for selective expression of cloned DNAs by T7 RNA polymerase. Gene 56:125-135.
33. Sabin, A. B. 1985. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J. Infect. Dis. 151:420-436.
34. Silvera, D., and R. Andino. Unpublished data.
35. 33b.Tang, S., R. Andino, and C. Miller. Unpublished data.
36. Trono, D., R. Andino, and D. Baltimore. 1988. An RNA sequence of hundreds of nucleotides at the 5′ end of poliovirus RNA is involved in allowing viral protein synthesis. J. Virol. 62:2291-2299.
37. Weiss, R. A. 1993. How does HIV cause AIDS? Science 260:1273-1279.